Dacomitinib, a second-generation irreversible pan-human EGFR tyrosine kinase inhibitor, has been shown to improve progression-free survival in patients with EGFR-mutant NSCLC but is frequently associated with cutaneous adverse effects collectively known as papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors (PRIDE) syndrome [2,3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.